Literature DB >> 15861932

Antifungal drugs and rational use of antifungals in treating invasive aspergillosis: the role of the hospital pharmacist.

Tiene G M Bauters1, Franky M A Buyle, Renaat Peleman, Hugo Robays.   

Abstract

AIM: This review discusses the most common used antifungal agents in the treatment of invasive fungal infections. In addition, guidelines for the treatment of invasive aspergillosis, as used in the Ghent University Hospital, are described. Moreover, the importance of determining the effectiveness of antifungal therapy as well as the potential role of the hospital pharmacist in the management of this infection is highlighted.
METHODS: A review of the English-language literature was conducted using the MEDLINE database and scientific websites. Search terms including antimycotics, antifungal therapy and invasive aspergillosis were used to refine the search, and preference was given to studies published after 1992. This was completed with recent treatment guidelines.
RESULTS: An overview of the most recent advances in antifungal therapy is described. In addition, a flowchart for treatment of invasive aspergillosis (proven, probable or possible) has been developed.
CONCLUSION: Invasive fungal infections will remain a frequent and important complication of modern medicine. Considering the clinical and financial outcome of invasive fungal infections, the role of the hospital pharmacist can be a paramount to the treatment.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15861932     DOI: 10.1007/s11096-004-1735-0

Source DB:  PubMed          Journal:  Pharm World Sci        ISSN: 0928-1231


  23 in total

Review 1.  Intravenous to oral (iv:po) anti-infective conversion therapy.

Authors:  G A Wetzstein
Journal:  Cancer Control       Date:  2000 Mar-Apr       Impact factor: 3.302

Review 2.  Echinocandins: a new class of antifungal.

Authors:  David W Denning
Journal:  J Antimicrob Chemother       Date:  2002-06       Impact factor: 5.790

Review 3.  Antifungal chemotherapy: advances and perspectives.

Authors:  Andreas H Groll; Thomas J Walsh
Journal:  Swiss Med Wkly       Date:  2002-06-15       Impact factor: 2.193

4.  Activity of SCH 56592 compared with those of fluconazole and itraconazole against Candida spp.

Authors:  D Law; C B Moore; D W Denning
Journal:  Antimicrob Agents Chemother       Date:  1997-10       Impact factor: 5.191

Review 5.  Current role of therapy with amphotericin B.

Authors:  R D Meyer
Journal:  Clin Infect Dis       Date:  1992-03       Impact factor: 9.079

Review 6.  Echinocandins and pneumocandins--a new antifungal class with a novel mode of action.

Authors:  D W Denning
Journal:  J Antimicrob Chemother       Date:  1997-11       Impact factor: 5.790

Review 7.  Current and emerging azole antifungal agents.

Authors:  D J Sheehan; C A Hitchcock; C M Sibley
Journal:  Clin Microbiol Rev       Date:  1999-01       Impact factor: 26.132

8.  Hospital pharmacists' reinforcement of guidelines for switching from parenteral to oral antibiotics: a pilot study.

Authors:  Vera von Gunten; Viviane Amos; Anne-Laure Sidler; Johnny Beney; Nicolas Troillet; Jean-Philippe Reymond
Journal:  Pharm World Sci       Date:  2003-04

Review 9.  Systemically administered antifungal agents. A review of their clinical pharmacology and therapeutic applications.

Authors:  C A Lyman; T J Walsh
Journal:  Drugs       Date:  1992-07       Impact factor: 9.546

10.  Safety, plasma concentrations, and efficacy of high-dose fluconazole in invasive mold infections.

Authors:  E J Anaissie; D P Kontoyiannis; C Huls; S E Vartivarian; C Karl; R A Prince; J Bosso; G P Bodey
Journal:  J Infect Dis       Date:  1995-08       Impact factor: 5.226

View more
  4 in total

1.  Posaconazole enhances the activity of amphotericin B against Aspergillus hyphae in vitro.

Authors:  Susanne Perkhofer; Helene Lugger; Manfred P Dierich; Cornelia Lass-Flörl
Journal:  Antimicrob Agents Chemother       Date:  2006-11-20       Impact factor: 5.191

2.  Interaction of 5-hydroxytryptamine (serotonin) against Aspergillus spp. in vitro.

Authors:  Susanne Perkhofer; Harald Niederegger; Gerhard Blum; Wolfgang Burgstaller; Maximilian Ledochowski; Manfred P Dierich; Cornelia Lass-Flörl
Journal:  Int J Antimicrob Agents       Date:  2007-02-02       Impact factor: 5.283

3.  The mitochondrial protein Bak is pivotal for gliotoxin-induced apoptosis and a critical host factor of Aspergillus fumigatus virulence in mice.

Authors:  Julian Pardo; Christin Urban; Eva M Galvez; Paul G Ekert; Uwe Müller; June Kwon-Chung; Mario Lobigs; Arno Müllbacher; Reinhard Wallich; Christoph Borner; Markus M Simon
Journal:  J Cell Biol       Date:  2006-08-07       Impact factor: 10.539

4.  Influence of amphotericin B and amphotericin B colloidal dispersion on the functions of human phagocytes in defence against Aspergillus species.

Authors:  S Perkhofer; G Blum; C Speth; A Mayr; M P Dierich; C Lass-Flörl
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-06       Impact factor: 5.103

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.